CANLI
Yükleniyor Veriler getiriliyor…
/ Makaleler / Scopus Detay
Scopus YÖKSİS Eşleşti

The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: A single-blind, randomised study

Human Psychopharmacology · Ocak 2011

YÖKSİS DOI Eşleşmesi Bulundu

Bu Scopus makalesi YÖKSİS veritabanında da kayıtlı. Aşağıda YÖKSİS verilerini görebilirsiniz.

YÖKSİS Kayıtları
The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor refractory obsessive compulsive disorder a single blind randomised study
Human Psychopharmacology: Clinical and Experimental · 2011 SSCI 31 atıf
PROFESÖR YAVUZ SELVİ →

Makale Bilgileri

DergiHuman Psychopharmacology
Yayın TarihiOcak 2011
Cilt / Sayfa26 · 51-57
Özet Objective: To investigate the comparative efficacy of aripiprazole and risperidone as augmenting agents in the treatment of obsessive-compulsive disorder (OCD) patients who did not show a ≥35% decrease in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) after 12-week monotherapy with selective serotonin reuptake inhibitors (SSRIs). Methods: The study consists of two different periods of treatment: a 12-week prospective period to determine resistance to SSRI treatment and an 8-week single-blind addition period for refractory patients only. Ninety patients were randomly assigned to receive one of the SSRI treatments. Sixty-nine patients (76.6%) completed the 12-week SSRI monotherapy period. Forty-one patients (59.4%) were considered refractory and were randomised to receive either risperidone (20 patients, 3 mgr daily) or aripiprazole (21 patients, 15 mgr daily) as augmentation to SSRI treatment. Sixteen patients (76.2%) in the aripiprazole group and 18 patients (84%) in the risperidone group completed the 8-week treatment period. Results: Eight patients (50%) in aripiprazole and 13 patients (72.2%) in risperidone group met response criteria of Y-BOCS decrease ≥35% at the end of the study. The risperidone group showed a significant improvement in Y-BOCS obsession scores compared with aripiprazole. Conclusions The present findings suggest that risperidone may be more effective than aripiprazole. Copyright © 2011 John Wiley & Sons, Ltd.

Yazarlar (6)

1
Yavuz Selvi
2
Abdullah Atli
3
Adem Aydin
4
Lutfullah Besiroglu
5
Pinar Guzel Ozdemir
6
Osman Ozdemir

Anahtar Kelimeler

Antipsychotic Obsessive-compulsive disorder Treatment-refractory

Kurumlar

Van Yüzüncü Yıl Üniversitesi
Van Turkey

Metrikler

48
Atıf
6
Yazar
3
Anahtar Kelime

Sistemimizdeki Yazarlar